Compare ServiceNow Inc (NOW) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance

ServiceNow (NOW) trades at $140.32, down 0.38% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.90, and its AI business surpassed $1 billion in annual contract value. Revenue grew to $13.28 billion in 2025, with a net income margin of 11.34%, though valuation multiples remain elevated with a P/E of 86.63.

The outlook is positive, supported by robust AI adoption and enterprise demand, but risks include high valuation, competitive pressures, and potential margin compression. Analysts are overwhelmingly bullish with an 86.96% buy rating and a consensus price target of $150.71, suggesting upside potential from current levels.

SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.

Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.